AGA Seeks to Make IBD Care Affordable and Equitable With New 12-Point Plan

Overview

The American Gastroenterological Association (AGA) has introduced a 12-point plan aimed at improving the quality of care for patients with inflammatory bowel disease (IBD).

Background

Inflammatory bowel disease (IBD) is a growing concern globally, with increasing prevalence and significant disparities in access to care. Patients often face obstacles such as prior authorization, step therapy, and limited access to specialists.

Data Highlights

No numerical data provided in the source material.

Key Findings

• The AGA's 12-point plan aims to enhance IBD care quality and accessibility.
• Collaboration among healthcare practitioners, insurance providers, and policymakers is essential.
• Key barriers identified include prior authorization, step therapy, and limited access to IBD specialists.
• The plan advocates for patient-centered multidisciplinary care and improved health literacy.
• Engagement with pharmaceutical partners is necessary to address drug costs.

Clinical Implications

The AGA has outlined initiatives to improve IBD care.

Conclusion

The AGA's 12-point plan addresses barriers in the healthcare system for patients with IBD.

Related Resources & Content

1. Sofia et al, Clinical Gastroenterology and Hepatology, 2024 -- AGA Position Statement: The Future of IBD Care in the United States
2. the new gastroenterologist — AGA launches patient-focused IBD Drug Guide
3. Journal of Crohn's and Colitis — Equitable access to inflammatory bowel disease care: challenges, strategies, and future directions
4. the new gastroenterologist — Hospital care for IBD gets practical refresh
5. The New Gastroenterologist — Advancing Gastrointestinal Innovation Through Strategic Investment
6. AGA launches patient-focused IBD Drug Guide
7. Equitable access to inflammatory bowel disease care: challenges, strategies, and future directions
8. Hospital care for IBD gets practical refresh
9. White Paper: American Gastroenterological Association Position Statement: The Future of IBD Care in the United States–Removing Barriers and Embracing Opportunities - Clinical Gastroenterology and Hepatology
10. AGA Living Clinical Practice Guideline on the Pharmacologic Management of Moderate-to-Severe Crohn’s Disease - ScienceDirect
11. Efficacy and safety of intravenous induction and subcutaneous maintenance therapy with guselkumab for patients with Crohn's disease (GALAXI-2 and GALAXI-3): 48-week results from two phase 3, randomised, placebo and active comparator-controlled, double-blind, triple-dummy trials - ScienceDirect